sarpogrelate has been researched along with Hypertension, Pulmonary in 6 studies
sarpogrelate: structure given in first source
Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study investigated whether sarpogrelate hydrochloride (SPG), a 5-HT2A receptor antagonist, alleviates chronic hypoxic pulmonary hypertension (CH-PH) in rats by stimulating apoptosis and inhibiting proliferation in pulmonary artery smooth muscle cells (PASMCs)." | 7.83 | The effects of the 5-HT2A receptor antagonist sarpogrelate hydrochloride on chronic hypoxic pulmonary hypertension in rats. ( Fan, FL; Geng, J; He, S; Liu, Y; Ma, Q; Meng, Y; Tian, H; Tian, HY; Zhang, D; Zhang, JB, 2016) |
| "The purpose of the present study was to determine if sarpogrelate hydrochloride (SPG), a serotonin 5HT2A receptor antagonist, prevented the development of chronic hypoxia-induced pulmonary hypertension (PH) and hypertensive pulmonary vascular remodeling." | 7.81 | Sarpogrelate hydrochloride, a serotonin 5HT2A receptor antagonist, ameliorates the development of chronic hypoxic pulmonary hypertension in rats. ( Ma, N; Maruyama, J; Maruyama, K; Mitani, Y; Nishikawa, M; Sawada, H; Yokochi, A; Zhang, E, 2015) |
| "The significance of serotonin in the pathogenesis of monocrotaline-induced pulmonary hypertension (MCT-PH) in rats, plasma serotonin concentrations, and the effect of a serotonin receptor antagonist administration in association with the number of proliferative cells were investigated." | 7.70 | Development of monocrotaline-induced pulmonary hypertension is attenuated by a serotonin receptor antagonist. ( Ito, M; Kasukawa, R; Miyata, M; Ohira, H; Sasajima, T; Sato, Y, 2000) |
| "This study investigated whether sarpogrelate hydrochloride (SPG), a 5-HT2A receptor antagonist, alleviates chronic hypoxic pulmonary hypertension (CH-PH) in rats by stimulating apoptosis and inhibiting proliferation in pulmonary artery smooth muscle cells (PASMCs)." | 3.83 | The effects of the 5-HT2A receptor antagonist sarpogrelate hydrochloride on chronic hypoxic pulmonary hypertension in rats. ( Fan, FL; Geng, J; He, S; Liu, Y; Ma, Q; Meng, Y; Tian, H; Tian, HY; Zhang, D; Zhang, JB, 2016) |
| "The purpose of the present study was to determine if sarpogrelate hydrochloride (SPG), a serotonin 5HT2A receptor antagonist, prevented the development of chronic hypoxia-induced pulmonary hypertension (PH) and hypertensive pulmonary vascular remodeling." | 3.81 | Sarpogrelate hydrochloride, a serotonin 5HT2A receptor antagonist, ameliorates the development of chronic hypoxic pulmonary hypertension in rats. ( Ma, N; Maruyama, J; Maruyama, K; Mitani, Y; Nishikawa, M; Sawada, H; Yokochi, A; Zhang, E, 2015) |
| "The significance of serotonin in the pathogenesis of monocrotaline-induced pulmonary hypertension (MCT-PH) in rats, plasma serotonin concentrations, and the effect of a serotonin receptor antagonist administration in association with the number of proliferative cells were investigated." | 3.70 | Development of monocrotaline-induced pulmonary hypertension is attenuated by a serotonin receptor antagonist. ( Ito, M; Kasukawa, R; Miyata, M; Ohira, H; Sasajima, T; Sato, Y, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, J | 1 |
| Tian, H | 2 |
| Liu, Y | 2 |
| Fan, F | 1 |
| Zhang, E | 1 |
| Maruyama, J | 1 |
| Yokochi, A | 1 |
| Mitani, Y | 1 |
| Sawada, H | 1 |
| Nishikawa, M | 1 |
| Ma, N | 1 |
| Maruyama, K | 1 |
| Geng, J | 1 |
| Fan, FL | 1 |
| He, S | 1 |
| Meng, Y | 1 |
| Zhang, D | 1 |
| Ma, Q | 1 |
| Zhang, JB | 1 |
| Tian, HY | 1 |
| Hironaka, E | 1 |
| Hongo, M | 1 |
| Sakai, A | 1 |
| Mawatari, E | 1 |
| Terasawa, F | 1 |
| Okumura, N | 1 |
| Yamazaki, A | 1 |
| Ushiyama, Y | 1 |
| Yazaki, Y | 1 |
| Kinoshita, O | 1 |
| Kawano, H | 1 |
| Sengyoku, H | 1 |
| Satoh, O | 1 |
| Urabe, S | 1 |
| Koide, Y | 1 |
| Yano, K | 1 |
| Miyata, M | 1 |
| Ito, M | 1 |
| Sasajima, T | 1 |
| Ohira, H | 1 |
| Sato, Y | 1 |
| Kasukawa, R | 1 |
6 other studies available for sarpogrelate and Hypertension, Pulmonary
| Article | Year |
|---|---|
Sarpogrelate attenuates pulmonary arterial hypertension via calcium/calcineurin axis.
Topics: Animals; Calcineurin; Calcium; Gene Expression; Hypertension, Pulmonary; Male; NFATC Transcription F | 2019 |
Sarpogrelate hydrochloride, a serotonin 5HT2A receptor antagonist, ameliorates the development of chronic hypoxic pulmonary hypertension in rats.
Topics: Animals; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Lung; Male; Nitric Oxide | 2015 |
The effects of the 5-HT2A receptor antagonist sarpogrelate hydrochloride on chronic hypoxic pulmonary hypertension in rats.
Topics: Animals; Apoptosis; Cell Proliferation; Chronic Disease; Hypertension, Pulmonary; Hypoxia; Male; Myo | 2016 |
Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats.
Topics: Animals; Endothelium, Vascular; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Nitric Oxide Syn | 2003 |
Marked improvement with sildenafil in a patient with idiopathic pulmonary arterial hypertension unresponsive to beraprost and sarpogrelate.
Topics: Adolescent; Drug Therapy, Combination; Epoprostenol; Humans; Hypertension, Pulmonary; Male; Piperazi | 2007 |
Development of monocrotaline-induced pulmonary hypertension is attenuated by a serotonin receptor antagonist.
Topics: Animals; Cell Division; Endothelium, Vascular; Hypertension, Pulmonary; Male; Monocrotaline; Prolife | 2000 |